P K Berger1, N K Pollock, E M Laing, S J Warden, K M Hill Gallant, D B Hausman, R A Tripp, L D McCabe, G P McCabe, C M Weaver, M Peacock, R D Lewis. 1. Department of Foods and Nutrition (P.K.B., E.M.L., D.B.H., R.D.L.), The University of Georgia, Athens, Georgia 30602; Department of Pediatrics (N.K.P.), Georgia Regents University, Augusta, Georgia 30912; Department of Physical Therapy (S.J.W.), Indiana University School of Health and Rehabilitation Sciences, and Department of Medicine (K.M.H.G., M.P.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Departments of Nutrition Science (K.M.H.G., L.D.M., C.M.W.) and Statistics (G.P.M.), Purdue University, West Lafayette, Indiana 47907; and Department of Infectious Diseases (R.A.T.), The University of Georgia, Athens, Georgia 30602.
Abstract
CONTEXT: Although animal studies suggest that adenovirus 36 (Ad36) infection is linked to obesity and systemic inflammation, human data are scant and equivocal. OBJECTIVE: Associations of Ad36 infection with total body adiposity and inflammatory-related markers were determined in 291 children aged 9-13 years (50% female, 49% black). DESIGN: Fasting blood samples were measured for presence of Ad36-specific antibodies and TNF-α, IL-6, vascular endothelial growth factor (VEGF), and monocyte chemoattractant protein-1 (MCP-1). Fat mass and fat-free soft tissue mass were measured by dual-energy X-ray absorptiometry. RESULTS: The overall prevalence of Ad36 seropositivity [Ad36(+)] was 42%. There was a higher percentage of Ad36(+) children in the highest tertiles of TNF-α and IL-6 compared with their respective middle and lowest tertiles (both P < .03). There was also a trend toward a higher prevalence of Ad36(+) children in the highest tertile of VEGF compared with tertiles 1 and 2 (P = .05). Multinomial logistic regression, adjusting for age, race, sex, and fat-free soft tissue mass, revealed that compared with children with the lowest TNF-α, IL-6, and VEGF levels (tertile 1), the adjusted odds ratios for Ad36(+) were 2.2 [95% confidence interval (CI) 1.2-4.0], 2.4 (95% CI 1.4-4.0), and 1.8 (95% CI 1.0-3.3), respectively, for those in the highest TNF-α, IL-6, and VEGF levels (tertile 3). No association was observed between Ad36(+) and greater levels of fat mass or MCP-1 (all P > .05). CONCLUSIONS: In children, our data suggest that Ad36(+) may be associated with biomarkers implicated in inflammation but not with greater levels of fat mass.
CONTEXT: Although animal studies suggest that adenovirus 36 (Ad36) infection is linked to obesity and systemic inflammation, human data are scant and equivocal. OBJECTIVE: Associations of Ad36 infection with total body adiposity and inflammatory-related markers were determined in 291 children aged 9-13 years (50% female, 49% black). DESIGN: Fasting blood samples were measured for presence of Ad36-specific antibodies and TNF-α, IL-6, vascular endothelial growth factor (VEGF), and monocyte chemoattractant protein-1 (MCP-1). Fat mass and fat-free soft tissue mass were measured by dual-energy X-ray absorptiometry. RESULTS: The overall prevalence of Ad36 seropositivity [Ad36(+)] was 42%. There was a higher percentage of Ad36(+) children in the highest tertiles of TNF-α and IL-6 compared with their respective middle and lowest tertiles (both P < .03). There was also a trend toward a higher prevalence of Ad36(+) children in the highest tertile of VEGF compared with tertiles 1 and 2 (P = .05). Multinomial logistic regression, adjusting for age, race, sex, and fat-free soft tissue mass, revealed that compared with children with the lowest TNF-α, IL-6, and VEGF levels (tertile 1), the adjusted odds ratios for Ad36(+) were 2.2 [95% confidence interval (CI) 1.2-4.0], 2.4 (95% CI 1.4-4.0), and 1.8 (95% CI 1.0-3.3), respectively, for those in the highest TNF-α, IL-6, and VEGF levels (tertile 3). No association was observed between Ad36(+) and greater levels of fat mass or MCP-1 (all P > .05). CONCLUSIONS: In children, our data suggest that Ad36(+) may be associated with biomarkers implicated in inflammation but not with greater levels of fat mass.
Authors: M Rathod; S D Vangipuram; B Krishnan; A R Heydari; T C Holland; N V Dhurandhar Journal: Int J Obes (Lond) Date: 2006-05-02 Impact factor: 5.095
Authors: M P Broderick; C J Hansen; M Irvine; D Metzgar; K Campbell; C Baker; K L Russell Journal: Int J Obes (Lond) Date: 2009-11-10 Impact factor: 5.095
Authors: Isela Parra-Rojas; Oscar Del Moral-Hernández; Aralia B Salgado-Bernabé; Iris P Guzmán-Guzmán; Lorenzo Salgado-Goytia; José F Muñoz-Valle Journal: Int J Endocrinol Date: 2013-11-13 Impact factor: 3.257
Authors: M A Sabin; D Burgner; R L Atkinson; Z Pei-Lun Lee; C G Magnussen; M Cheung; M Kähönen; T Lehtimäki; E Jokinen; T Laitinen; N Hutri-Kähönen; J S A Viikari; M Juonala; O T Raitakari Journal: Int J Obes (Lond) Date: 2015-06-09 Impact factor: 5.095
Authors: Jaime da Silva Fernandes; Fabiana Schuelter-Trevisol; Ana Carolina Lobor Cancelier; Helena Caetano Gonçalves E Silva; Daiana Gomes de Sousa; Richard L Atkinson; Daisson José Trevisol Journal: Int J Obes (Lond) Date: 2021-03-22 Impact factor: 5.095
Authors: Ana Carolina Lobor Cancelier; Nikhil V Dhurandhar; Swetha Peddibhotla; Richard L Atkinson; Helena C G Silva; Daisson J Trevisol; Fabiana Schuelter-Trevisol Journal: J Pediatr (Rio J) Date: 2020-09-07 Impact factor: 2.990